![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CD Funk, L Furci, N Moran and GA Fitzgerald
Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232.
Thromboxane A2, a potent platelet agonist and vasoconstrictor, exerts its actions via specific G protein-coupled receptors. cDNAs encoding the full length thromboxane receptor have been isolated from human placenta mRNA by reverse transcriptase-polymerase chain reaction. An expression construct, under control of the cytomegalovirus promoter, was introduced into human embryonic kidney 293 cells. Membranes from transfected cells bound the thromboxane antagonist SQ29,548 and the agonist [15-(1 alpha,2 beta(5z)-3 alpha(1E,3S)-4 alpha)]-7-[3-(3- hydroxy-4-(p- iodophenoxy)-1-butenyl)-7-oxabicyclo[2,2,1]hept-2-yl]-5- heptenoic acid) with high affinities, and significantly more receptors were expressed in these cells, compared with platelet preparations. The putative seventh transmembrane segment is highly related in all cloned members of the eicosanoid receptor family and forms a critical portion of the ligand binding pocket for G protein-coupled receptors. Several point mutations in this segment were generated. Binding of SQ29,548 was virtually abolished in cells transfected with all the variant receptor constructs. However, one receptor variant (TxR-W299L), in which a tryptophan at position 299 was substituted for a leucine residue, allowed a definite discrimination between agonist and antagonist binding sites in competition and saturation binding experiments. An antibody directed toward the third intracellular loop of the thromboxane receptor was able to immunoprecipitate native thromboxane receptor in solubilized membranes from human erythroleukemia cells and transfected cells.
This article has been cited by other articles:
|
|
 |
|
  F. T. Khasawneh, J.-S. Huang, J. W. Turek, and G. C. L. Breton Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein J. Biol. Chem., September 15, 2006; 281(37): 26951 - 26965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Hata, T. P. Lybrand, and R. M. Breyer Identification of Determinants of Ligand Binding Affinity and Selectivity in the Prostaglandin D2 Receptor CRTH2 J. Biol. Chem., September 16, 2005; 280(37): 32442 - 32451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Wilson, A. M. Roche, E. Kostetskaia, and E. M. Smyth Dimerization of the Human Receptors for Prostacyclin and Thromboxane Facilitates Thromboxane Receptor-mediated cAMP Generation J. Biol. Chem., December 17, 2004; 279(51): 53036 - 53047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Qiao, D. Reynaud, P. Demin, P. V. Halushka, and C. R. Pace-Asciak The Thromboxane Receptor Antagonist PBT-3, a Hepoxilin Stable Analog, Selectively Antagonizes the TP{alpha} Isoform in Transfected COS-7 Cells J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1142 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-P. So, J. Wu, G. Huang, A. Huang, D. Li, and K.-H. Ruan Identification of Residues Important for Ligand Binding of Thromboxane A2 Receptor in the Second Extracellular Loop Using the NMR Experiment-guided Mutagenesis Approach J. Biol. Chem., March 21, 2003; 278(13): 10922 - 10927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Turek, T. Halmos, N. L. Sullivan, K. Antonakis, and G. C. Le Breton Mapping of a Ligand-binding Site for the Human Thromboxane A2 Receptor Protein J. Biol. Chem., May 3, 2002; 277(19): 16791 - 16797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. S. Paul, J. Jin, and S. P. Kunapuli Molecular Mechanism of Thromboxane A2-induced Platelet Aggregation. ESSENTIAL ROLE FOR P2TAC and alpha 2A RECEPTORS J. Biol. Chem., October 8, 1999; 274(41): 29108 - 29114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid Receptors: Structures, Properties, and Functions Physiol Rev, October 1, 1999; 79(4): 1193 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Neuschäfer-Rube, M. Oppermann, U. Möller, U. Böer, and G. P. Püschel Agonist-Induced Phosphorylation by G Protein-Coupled Receptor Kinases of the EP4 Receptor Carboxyl-Terminal Domain in an EP3/EP4 Prostaglandin E2 Receptor Hybrid Mol. Pharmacol., August 1, 1999; 56(2): 419 - 428. [Abstract] [Full Text]
|
|
|
|
|
|
A. Habib, G. A. FitzGerald, and J. Maclouf Phosphorylation of the Thromboxane Receptor alpha , the Predominant Isoform Expressed in Human Platelets J. Biol. Chem., January 29, 1999; 274(5): 2645 - 2651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Kedzie, J. E. Donello, H. A. Krauss, J. W. Regan, and D. W. Gil A Single Amino-Acid Substitution in the EP2 Prostaglandin Receptor Confers Responsiveness to Prostacyclin Analogs Mol. Pharmacol., September 1, 1998; 54(3): 584 - 590. [Abstract] [Full Text]
|
|
|
|
|
|
M. T. Walsh, J. F. Foley, and B. T. Kinsella Characterization of the Role of N-Linked Glycosylation on the Cell Signaling and Expression of the Human Thromboxane A2 Receptor Alpha and Beta Isoforms J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1026 - 1036. [Abstract] [Full Text]
|
|
|
|
|
|
T. H. Ji, M. Grossmann, and I. Ji G Protein-coupled Receptors. I. DIVERSITY OF RECEPTOR-LIGAND INTERACTIONS J. Biol. Chem., July 10, 1998; 273(28): 17299 - 17302. [Full Text] [PDF]
|
|
|
|
|
|
T. Kobayashi, M. Kiriyama, T. Hirata, M. Hirata, F. Ushikubi, and S. Narumiya Identification of Domains Conferring Ligand Binding Specificity to the Prostanoid Receptor. STUDIES ON CHIMERIC PROSTACYCLIN/PROSTAGLANDIN D RECEPTORS J. Biol. Chem., June 13, 1997; 272(24): 15154 - 15160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II, M. G. Davis, and D. D. D'Angelo Structural Determinants for Agonist Binding Affinity to Thromboxane/Prostaglandin Endoperoxide (TP) Receptors. ANALYSIS OF CHIMERIC RAT/HUMAN TP RECEPTORS J. Biol. Chem., May 9, 1997; 272(19): 12399 - 12405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Audoly and R. M. Breyer Substitution of Charged Amino Acid Residues in Transmembrane Regions 6 and 7 Affect Ligand Binding and Signal Transduction of the Prostaglandin EP3 Receptor Mol. Pharmacol., January 1, 1997; 51(1): 61 - 68. [Abstract] [Full Text]
|
|
|
|
|
|
E. Okuda-Ashitaka, K. Sakamoto, T. Ezashi, K. Miwa, S. Ito, and O. Hayaishi Suppression of Prostaglandin E Receptor Signaling by the Variant Form of EP1 Subtype J. Biol. Chem., December 6, 1996; 271(49): 31255 - 31261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Negishi, A. Irie, Y. Sugimoto, T. Namba, and A. Ichikawa Selective Coupling of Prostaglandin E Receptor EP3D to G[IMAGE] and G[IMAGE] through Interaction of [IMAGE]-Carboxylic Acid of Agonist and Arginine Residue of Seventh Transmembrane Domain J. Biol. Chem., July 7, 1995; 270(27): 16122 - 16127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pratico, J. A. Lawson, and G. A. FitzGerald Cylooxygenase-dependent Formation of the Isoprostane, 8-Epi Prostaglandin F[IMAGE] J. Biol. Chem., April 28, 1995; 270(17): 9800 - 9808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tokita, S. J. Hocart, T. Katsuno, S. A. Mantey, D. H. Coy, and R. T. Jensen Tyrosine 220 in the 5th Transmembrane Domain of the Neuromedin B Receptor Is Critical for the High Selectivity of the Peptoid Antagonist PD168368 J. Biol. Chem., January 5, 2001; 276(1): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tokita, T. Katsuno, S. J. Hocart, D. H. Coy, M. Llinares, J. Martinez, and R. T. Jensen Molecular Basis for Selectivity of High Affinity Peptide Antagonists for the Gastrin-releasing Peptide Receptor J. Biol. Chem., September 21, 2001; 276(39): 36652 - 36663. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
